Mechanisms coupling the hemostatic system to colitis-associated cancer

Thrombosis Research

Volumn 125, Issue , 2010, Pages S39-S43

  Palumbo, Joseph S ^a   Degen, Jay L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Coagulation Factors; Colitis; Colon Cancer; Inflammation

Indexed keywords

BLOOD CLOTTING FACTOR;

ANIMAL; BLOOD; COLITIS; COLON TUMOR; HEMOSTASIS; HUMAN; IMMUNOLOGY; REVIEW;

ANIMALS; BLOOD COAGULATION FACTORS; COLITIS; COLONIC NEOPLASMS; HEMOSTASIS; HUMANS;

EID: 77955481551     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70011-6     Document Type: Article

References (59)

1. Balkwill, F, Mantovani, A, Inflammation and cancer: back to Virchow?. Lancet 357:9255 (2001), 539–545.
2. Itzkowitz, SH, Yio, X, Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:1 (2004), G7–G17.
3. Matanoski, G, Tao, XG, Almon, L, Adade, AA, Davies-Cole, JO, Demographics and tumor characteristics of colorectal cancers in the United States, 1998–2001. Cancer 107:5 Suppl (2006), 1112–1120.
4. Weir, HK, Thun, MJ, Hankey, BF, Ries, LA, Howe, HL, Wingo, PA, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:17 (2003), 1276–1299.
5. Xie, J, Itzkowitz, SH, Cancer in inflammatory bowel disease. World J Gastroenterol 14:3 (2008), 378–389.
6. Fujiwara, I, Yashiro, M, Kubo, N, Maeda, K, Hirakawa, K, Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum 51:9 (2008), 1387–1394.
7. Hussain, SP, Hofseth, LJ, Harris, CC, Radical causes of cancer. Nat Rev Cancer 3:4 (2003), 276–285.
8. Fantini, MC, Pallone, F, Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 9:5 (2008), 375–380.
9. Danese, S, Papa, A, Saibeni, S, Repici, A, Malesci, A, Vecchi, M, Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 102:1 (2007), 174–186.
10. Lee, AY, Levine, MN, Venous thromboembolism and cancer: risks and outcomes. Circulation 107:23 Suppl 1 (2003), I17–I21.
11. Kumar, S, Ghoshal, UC, Aggarwal, R, Saraswat, VA, Choudhuri, G, Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 19:11 (2004), 1247–1252.
12. Kilic, M, Yoldas, O, Keskek, M, Ertan, T, Tez, M, Gocmen, E, et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 10:3 (2008), 238–241.
13. Oya, M, Akiyama, Y, Okuyama, T, Ishikawa, H, High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 31:8 (2001), 388–394.
14. Anthoni, C, Russell, J, Wood, KC, Stokes, KY, Vowinkel, T, Kirchhofer, D, et al. Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis. J Exp Med 204:7 (2007), 1595–1601.
15. Coughlin, SR, Camerer, E, PARticipation in inflammation. J Clin Invest 111:1 (2003), 25–27.
16. Cenac, N, Cellars, L, Steinhoff, M, Andrade-Gordon, P, Hollenberg, MD, Wallace, JL, et al. Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis 11:9 (2005), 792–798.
17. Vergnolle, N, Cellars, L, Mencarelli, A, Rizzo, G, Swaminathan, S, Beck, P, et al. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 114:10 (2004), 1444–1456.
18. Scaldaferri, F, Sans, M, Vetrano, S, Graziani, C, De Cristofaro, R, Gerlitz, B, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 117:7 (2007), 1951–1960.
19. Esmon, CT, Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 32:Suppl 1 (2006), 49–60.
20. Vowinkel, T, Wood, KC, Stokes, KY, Russell, J, Tailor, A, Anthoni, C, et al. Mechanisms of platelet and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol 293:5 (2007), G1054–G1060.
21. Irving, PM, Macey, MG, Shah, U, Webb, L, Langmead, L, Rampton, DS, Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 10:4 (2004), 361–372.
22. He, G, Ouyang, Q, Chen, D, Li, F, Zhou, J, The microvascular thrombi of colonic tissue in ulcerative colitis. Dig Dis Sci 52:9 (2007), 2236–2240.
23. Weyrich, AS, Zimmerman, GA, Platelets: signaling cells in the immune continuum. Trends Immunol 25:9 (2004), 489–495.
24. Flick, MJ, Du, X, Degen, JL, Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo. Exp Biol Med (Maywood) 229:11 (2004), 1105–1110.
25. Rubel, C, Fernandez, GC, Dran, G, Bompadre, MB, Isturiz, MA, Palermo, MS, Fibrinogen promotes neutrophil activation and delays apoptosis. J Immunol 166:3 (2001), 2002–2010.
26. Rubel, C, Fernandez, GC, Rosa, FA, Gomez, S, Bompadre, MB, Coso, OA, et al. Soluble fibrinogen modulates neutrophil functionality through the activation of an extracellular signal-regulated kinase-dependent pathway. J Immunol 168:7 (2002), 3527–3535.
27. Rubel, C, Gomez, S, Fernandez, GC, Isturiz, MA, Caamano, J, Palermo, MS, Fibrinogen-CD11b/CD18 interaction activates the NF-kappa B pathway and delays apoptosis in human neutrophils. Eur J Immunol 33:5 (2003), 1429–1438.
28. Sitrin, RG, Pan, PM, Srikanth, S, Todd, RF 3rd, Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol 161:3 (1998), 1462–1470.
29. Smiley, ST, King, JA, Hancock, WW, Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167:5 (2001), 2887–2894.
30. Adams, RA, Bauer, J, Flick, MJ, Sikorski, SL, Nuriel, T, Lassmann, H, et al. The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 204:3 (2007), 571–582.
31. Degen, JL, Bugge, TH, Goguen, JD, Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 5:Suppl 1 (2007), 24–31.
32. Flick, MJ, Du, X, Witte, DP, Jirouskova, M, Soloviev, DA, Busuttil, SJ, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 113:11 (2004), 1596–1606.
33. Flick, MJ, LaJeunesse, CM, Talmage, KE, Witte, DP, Palumbo, JS, Pinkerton, MD, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 117:11 (2007), 3224–3235.
34. Laurens, N, Koolwijk, P, de Maat, MP, Fibrin structure and wound healing. J Thromb Haemost 4:5 (2006), 932–939.
35. Bach, TL, Barsigian, C, Yaen, CH, Martinez, J, Endothelial cell VE-cadherin functions as a receptor for the beta15–42 sequence of fibrin. J Biol Chem 273:46 (1998), 30719–30728.
36. Holmback, K, Danton, MJ, Suh, TT, Daugherty, CC, Degen, JL, Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. Embo J 15:21 (1996), 5760–5771.
37. Schick, PK, Wojenski, CM, He, X, Walker, J, Marcinkiewicz, C, Niewiarowski, S, Integrins involved in the adhesion of megakaryocytes to fibronectin and fibrinogen. Blood 92:8 (1998), 2650–2656.
38. Ugarova, TP, Yakubenko, VP, Recognition of fibrinogen by leukocyte integrins. Ann N Y Acad Sci 936 (2001), 368–385.
39. Degen, JL, Palumbo, JS, Mechanisms linking hemostatic factors to tumor growth in mice. Pathophysiol Haemost Thromb 33:Suppl 1 (2003), 31–35.
40. Palumbo, JS, Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 34:2 (2008), 154–160.
41. Staton, CA, Brown, NJ, Lewis, CE, The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin Biol Ther 3:7 (2003), 1105–1120.
42. Wojtukiewicz, MZ, Sierko, E, Rak, J, Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 30:1 (2004), 5–20.
43. Palumbo, JS, Potter, JM, Kaplan, LS, Talmage, K, Jackson, DG, Degen, JL, Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62:23 (2002 Dec 1), 6966–6972.
44. Palumbo, JS, Kombrinck, KW, Drew, AF, Grimes, TS, Kiser, JH, Degen, JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96:10 (2000), 3302–3309.
45. Palumbo, JS, Talmage, KE, Massari, JV, La Jeunesse, CM, Flick, MJ, Kombrinck, KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:1 (2005), 178–185.
46. Palumbo, JS, Talmage, KE, Massari, JV, La Jeunesse, CM, Flick, MJ, Kombrinck, KW, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood, 19, 2007, 19.
47. Camerer, E, Qazi, AA, Duong, DN, Cornelissen, I, Advincula, R, Coughlin, SR, Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:2 (2004), 397–401.
48. Neufert, C, Becker, C, Neurath, MF, An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2:8 (2007), 1998–2004.
49. Steinbrecher, KA, Horowitz, N, Blevins, EA, Barney, KA, Shaw, MA, Harmel-Laws, E, et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin aMb2 engagement of fibrinogen. Cancer Res, 2009 in press.
50. Evans, R, Patzak, I, Svensson, L, De Filippo, K, Jones, K, McDowall, A, et al. Integrins in immunity. J Cell Sci 122:Pt 2 (2009), 215–225.
51. Mayadas, TN, Cullere, X, Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol 26:7 (2005), 388–395.
52. Pluskota, E, Soloviev, DA, Szpak, D, Weber, C, Plow, EF, Neutrophil apoptosis: selective regulation by different ligands of integrin alphaMbeta2. J Immunol 181:5 (2008), 3609–3619.
53. Steinbrecher, KA, Harmel-Laws, E, Sitcheran, R, Baldwin, AS, Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol 180:4 (2008), 2588–2599.
54. Schulzke, JD, Bojarski, C, Zeissig, S, Heller, F, Gitter, AH, Fromm, M, Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci 1072 (2006), 288–299.
55. Marini, M, Bamias, G, Rivera-Nieves, J, Moskaluk, CA, Hoang, SB, Ross, WG, et al. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA 100:14 (2003 Jul 8), 8366–8371.
56. Becker, C, Fantini, MC, Wirtz, S, Nikolaev, A, Lehr, HA, Galle, PR, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4:2 (2005), 217–220.
57. Grivennikov, S, Karin, E, Terzic, J, Mucida, D, Yu, GY, Vallabhapurapu, S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:2 (2009), 103–113.
58. Kwon, KH, Murakami, A, Hayashi, R, Ohigashi, H, Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 337:2 (2005), 647–654.
59. Ito, R, Shin-Ya, M, Kishida, T, Urano, A, Takada, R, Sakagami, J, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 146:2 (2006), 330–338.